Publications by authors named "David R Ferry"

Claim this Profile
S
Simple ammonium salts acting on sigma-1 receptors yield potential treatments for cancer and depression.
James M Brimson, Kiran K Akula, Haider Abbas, David R Ferry, Shrinivas K Kulkarni

Sci Rep· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hazards of Using When Performing Ligand Binding Assays: Lessons From the Sigma-1 and Sigma-2 Receptors.
Haider Abbas, Preeti Borde, Gary B Willars, David R Ferry, Stephen T Safrany

Front Pharmacol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer.
Egbert F Smit, Edward B Garon, Martin Reck, Federico Cappuzzo, Paolo Bidoli, David R Ferry

Cancer Chemother Pharmacol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer.
Russell D Petty, Asa Dahle-Smith, David A J Stevenson, Aileen Osborne, Doreen Massie, David R Ferry

J Clin Oncol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.
Paul Ruff, David R Ferry, Radek Lakomỳ, Jana Prausová, Guy A Van Hazel

Eur J Cancer· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
Susan J Dutton, David R Ferry, Jane M Blazeby, Haider Abbas, Asa Dahle-Smith

Lancet Oncol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
Charles S Fuchs, Jiri Tomasek, Cho Jae Yong, Filip Dumitru, Rodolfo Passalacqua, David R Ferry

Lancet· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Josep Tabernero, Eric Van Cutsem, Radek Lakomý, Jana Prausová, Paul Ruff, David R Ferry

Eur J Cancer· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.
Leonard W Seymour, David R Ferry, David J Kerr, Daniel Rea, Maggie Whitlock

Int J Oncol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma.
Robert J Jones, Robert E Hawkins, Martin M Eatock, David R Ferry, Ferry A L M Eskens

Cancer Chemother Pharmacol· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response.
David R Ferry, Mark Anderson, Kate Beddard, Simon Tomlinson, Paul Atherfold

Clin Cancer Res· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
Matthew T Seymour, Timothy S Maughan, Jonathan A Ledermann, Clare Topham, Roger James, David R Ferry

Lancet· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.
Leonard W Seymour, David R Ferry, David Anderson, Stuart Hesslewood, Peter J Julyan

J Clin Oncol· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis